Cointime

CRISPR Therapeutics

company

About

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

  • 101 - 250

Highlights

Total Funding Amount
$89M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Series B
Last Funding Money Raised
$29M
Industries
Biopharma,Biotechnology,Genetics,Medical
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.

CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$89M
CRISPR Therapeutics has raised a total of $89M in funding over 2 rounds. Their latest funding was raised on Apr 30, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 30, 2015 Series B $29M 2 Bayer Global Investments — Detail
Apr 29, 2015 Series A $35M 1 — — Detail
Apr 24, 2014 Series A $25M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
2
2
CRISPR Therapeutics is funded by 2 investors. Bayer Global Investments and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Bayer Global Investments Yes Series B
Versant Ventures — Series B
Cointime
เนื้อหา
บริษัท